Clinical Trial Update: Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation [Phase 3]

View source ↗

Summary

A Phase 3 study of ivacaftor in cystic fibrosis patients aged 12 and older with the G551D CFTR mutation completed, and results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Ivacaftor (ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2012-08-21